While ED is more common in men older than age 65, most men older than age 40 experience occasional difficulty; it is estimated that more than 50% of men older than age 40 report periodic episodes of ED. Despite the high number of cases, impotence is greatly undertreated, with only an estimated 15% of men seeking help from a physician due to the fact that they view the condition as personal or embarrassing.
Since the launch of Pfizer's oral drug Viagra (sildenafil) in 1998, there has been a considerable increase in public awareness of ED due to extensive marketing by leading drug manufacturers. As a result, the worldwide market for oral ED drugs has reached more than $4.2 billion.
The U.S. market for ED therapies (defined in this report as including prescription ED drugs and penile implants) is expected to continue stable, moderate growth over the next 5 years. Valued at more than $1.9 billion in 2010, the market is expected to increase at a healthy compound annual rate of 5.1%, with sales reaching more than $2.5 billion in 2015. The U.S. ED therapies market is expected to benefit not only from continued strong demand but from highly positive demographic trends, including a large, growing ED population, strong advertising/marketing, emerging next-generation ED therapies, launch of several lower cost generic drugs, and the continued adoption of improved penile implant systems.
This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging drugs, technology and opportunities. Covered topics in this report include erectile dysfunction drugs (existing and emerging oral and topical ED therapies), injectable and intraurethral agents, vacuum constriction devices, penile implants, and alternative treatments.
EXECUTIVE SUMMARY i. Causes and Prevention ii. Diagnosis and Treatment a. Oral Drug Therapy b. Injectable and Intraurethral Drug Therapy c. Vacuum Pump Therapy d. Surgery/Penile Prosthesis Implantation iii. Erectile Dysfunction Therapies Market a. Drug Therapy b. Penile Implants iv. Methodology Exhibit ES-1: Erectile Dysfunction Therapies, Combined Market Forecast, 2010-2015 1. CLINICAL OVERVIEW OF ERECTILE DYSFUNCTION 1.1 Causes and Prevention 1.2 Diagnosis and Treatment 1.2.1 Oral Drug Therapy 1.2.2 Injectable and Intraurethral Drug Therapy 1.2.3 Vacuum Pump Therapy 1.2.4 Surgery/Penile Prosthesis Implantation 1.3 Emerging Treatments 2. ERECTILE DYSFUNCTION THERAPIES MARKET 2.1 Drug Therapy 2.1.1 Oral Agents 188.8.131.52 Eli Lilly 184.108.40.206 Bayer HealthCare/Bayer 220.127.116.11 Pfizer 2.1.2 Injectable and Intraurethral Agents 18.104.22.168 Pfizer 22.214.171.124 Meda Pharmaceticals/Meda 2.1.3 Emerging Drugs 126.96.36.199 Oral Agents 188.8.131.52.1 Dong-A PharmTech/Dong-A Pharmaceutical 184.108.40.206.2 Palatin Technologies 220.127.116.11.3 Sanofi-aventis 18.104.22.168.4 SK Chemicals/SK Group 22.214.171.124.5 Vivus 126.96.36.199.6 Discontinued Clinical Development Programs 188.8.131.52.6.1 NitroMed 184.108.40.206.6.2 Novartis 220.127.116.11.6.3 Pfizer 18.104.22.168 Topical Agents 22.214.171.124.1 Futura Medical 126.96.36.199.2 Apricus Biosciences 2.1.4 Alternative Treatments 188.8.131.52 Pomegranate Extract 184.108.40.206 Testosterone Replacement Therapy 220.127.116.11 Yohimbine 18.104.22.168 Over-the-Counter Herbal Treatments 2.2 Penile Implants 2.2.1 Inflatable Implants 22.214.171.124 American Medical Systems/Endo Pharmaceuticals 126.96.36.199 Coloplast 2.2.2 Noninflatable Implants 188.8.131.52 American Medical Systems/Endo Pharmaceuticals 184.108.40.206 Coloplast 2.3 Vacuum Constriction Devices 2.3.1 Augusta Medical Systems 2.3.2 Timm Medical Technologies/Actient Pharmaceuticals 2.3.3 Post-T-Vac Medical 2.4 Market Analysis 2.4.1 Drug Therapy Market 220.127.116.11 Patient Volumes 18.104.22.168 Market Forecast 22.214.171.124 Competitive Analysis 2.4.2 Penile Implants Market 126.96.36.199 Procedure Volumes 188.8.131.52 Market Forecast 184.108.40.206 Competitive Analysis Exhibit 2-1: Comparative Advantages and Disadvantages of Cialis, Levitra, STAXYN, and Viagra Exhibit 2-2: Erectile Function Improvement Using Low-Dose Once-Daily Cialis Exhibit 2-3: Erectile Function Improvement Using Low-Dose Once-Daily Cialisin Patients with Diabetes Exhibit 2-4: Erectile Function Improvement Using Low-Dose Once-Daily Cialis in Patients with Controlled Hypertension or Cardiovascular Disease Exhibit 2-5: Erection Confidence Improvement Using Low-Dose Once-Daily Cialis Exhibit 2-6: Common Adverse Events Associated with the Use of Low-Dose Once-Daily Cialis Exhibit 2-7: Erectile Function Improvement Using High-Dose Cialis Exhibit 2-8: Erectile Function Improvement Using High-Dose Cialis in Patients with Diabetes Exhibit 2-9: Erectile Function Improvement Using High-Dose Cialis in Patients with Controlled Hypertension or Cardiovascular Disease Exhibit 2-10: Erection Confidence Improvement Using High-Dose Cialis Exhibit 2-11: Common Adverse Events Associated with the Use of High-Dose Cialis Exhibit 2-12: STAXYN Orally Disintegrating Tablets Exhibit 2-13: Common Adverse Events Associated with the Use of STAXYN Exhibit 2-14: Erectile Function Improvement Using Viagra, Pivotal Efficacy Results Exhibit 2-15: Steps Involved in the Use of the MUSE Transurethral System Exhibit 2-16: 2011, Selected Emerging Erectile Dysfunction Products Exhibit 2-17: Benefits and Risks of Penile Implants Exhibit 2-18: Advantages and Disadvantages of the AMS 700 Inflatable Penile Implant Exhibit 2-19: The AMS 700 LGX Inflatable Penile Implant Exhibit 2-20: Advantages and Disadvantages of the AMS Ambicor Inflatable Penile Implant Exhibit 2-21: The Titan and Titan OTR Inflatable Penile Prostheses Exhibit 2-22: The Genesis Flexible Rod Implant Exhibit 2-23: The SOMAerectStf Vacuum Constriction Device Exhibit 2-24: The Vitality OTC Vacuum Constriction Device Exhibit 2-25: The Osbon ErecAid Vacuum Therapy System Exhibit 2-26: The BOSS 2000-3 and MVP 700 Vacuum Constriction Devices Exhibit 2-27: Erectile Dysfunction Drug Therapy, Patient Volumes Forecast, 2010-2015 Exhibit 2-28: Erectile Dysfunction Drug Therapy, Market Forecast, 2010-2015 Exhibit 2-29: 2010, Erectile Dysfunction Drug Therapy Market, Share by Supplier Exhibit 2-30: Penile Prosthesis Implantation, Procedure Volumes Forecast, 2010-2015 Exhibit 2-31: Penile Implants, Market Forecast, 2010-2015 Exhibit 2-32: 2010, Penile Implants Market, Share by Supplier 3. COMPANY PROFILES 3.1 American Medical Systems, Inc./Endo Pharmaceuticals Holdings, Inc. 3.2 Apricus Biosciences, Inc. 3.3 Bayer AG 3.4 Futura Medical PLC 3.5 Eli Lilly and Company 3.6 Pfizer, Inc. 3.7 Reckitt Benckiser PLC 3.8 Vivus, Inc. APPENDIX: COMPANY LISTING